• Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month
Page
  1. 1
    1
  2. 2
    2
  3. 3
    3
  4. 4
    4
  5. 5
    5
  6. 6
    6
  7. 7
    7
  8. 8
    8
  9. 9
    9
  10. 10
    10
  11. 11
    11
  12. 12
    12

GSK case study

Extracts from this document...

Introduction

Case Study on: GlaxoSmithKline Case OBJECTIVE: "GSK" TO SUPPLY ANTIRETROVIRALS AND ANTI-MALARIALS AT SUSTAINABLE PREFERENTIAL PRICES FOR ELIGIBLE CUSTOMERS IN THE LEAST DEVELOPED COUNTRIES AND ALL SUB-SAHARAN AFRICAN COUNTRIES. Eligible customers include the public sector, not-for-profit NGOs, aid agencies, UN agencies and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. Additionally, because of the gravity of the situation in sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics are also eligible. MADE BY: JIGAR.R.RAJPURA X-01824544 Sustainable Preferential Pricing Arrangements GlaxoSmithKline has offered preferential pricing for our HIV/AIDS medicines since 1997. They placed a high priority on their prices being sustainable. This means setting prices at levels that meet their costs, thereby ensuring they can sustain supply of these high-quality products for as long as they are needed. The Promise In 'Facing the Challenge' it is promised to: � extend preferential pricing to more products, countries and customers; � supply antiretrovirals and anti-malarials at preferential prices to public sector customers and not-for-profit organisations in 63 countries - all the Least Developed Countries of the world and all of sub-Saharan Africa; � supply ARV therapy at preferential prices to employers in sub-Saharan Africa who provide HIV/AIDS care and treatment directly to their staff through their own workplace clinics; � make thier ARVs and anti-malarials available at preferential prices to international purchase funds; � set up pilot projects with non-governmental organisations (NGOs) ...read more.

Middle

GRAPH A: SUPPLY ARRANGEMENTS BY CUSTOMER TYPE GRAPH B: CUMULATIVE SHIPMENTS OF COMBIVIR TABLETS 100 80 60 40 Employers Public Hospitals NGOs Govt Non AAI AAI 8000000 7000000 6000000 5000000 4000000 3000000 Combivir tablets 20 0 Q4 2000 Q1 2001 Q2 2001 Q3 2001 Q4 2001 Q1 2002 Q2 2002 2000000 1000000 0 Q1 2001 Q2 2001 Q3 2001 Q4 2001 Q1 2002 Q2 2002 Research and Development Continued investment in research into diseases that affect the developing world is essential to long-term improvement in the health of people in these regions, not least because of challenges such as development of drug resistance to current treatments and poor patient adherence. For neglected communicable diseases, GlaxoSmithKline already has one of the most extensive portfolios of novel products and development projects in the industry. We are the only company currently involved in R&D for both the prevention and treatment of all three top priority diseases of the World Health Organization: malaria, tuberculosis and HIV/AIDS. And we currently have between 20 and 30 R&D projects and programmes of relevance to the developing world, of which ten are aimed at producing medicines primarily for developing countries.GSK frequently pursues a public/private partnership (PPP) model for R&D into diseases of the developing world. ...read more.

Conclusion

1987 - Burroughs Wellcome (a GSK legacy company) introduces the first antiretroviral (ARV), zidovudine (AZT). 1992 - GSK establishes Positive Action. 1994 - US Food and Drug Administration (FDA) approves GSK's Retrovir for the prevention of mother-to-child transmission of HIV. 1996 - Combination therapy involving a 'cocktail' of drugs promises longer AIDS-free survival. 1997 - FDA approves GSK's Combivir, the first product to combine two ARVs in a single tablet. GSK is the first company to sell an ARV therapy at highly discounted prices to sub-Saharan Africa. 2000 - FDA approves GSK's Trizivir, the first combination of three ARVs in a single tablet. 2001 - 47 million people are infected with HIV, 26 million of these live in Africa. GSK grants its first voluntary licence for the manufacture of generic versions of our ARVs in South Africa. 2007 - HIV infection is no longer a death sentence for people in the developed world, but the epidemic is increasing in Africa and Asia.GSK remains to work efficiently in the tackling of AIDS. REFRENCES: 1) http://www.gsk.com/responsibility/cr-review-2006/case-studies/aids.htm 2) In May 2002 we published 'Performance with Integrity - a Review of GlaxoSmithKline's Commitment to Society and the Environment'. This publication expands on the information on medicines for the developing world in the review which can be found at: www.gsk.com/ser/2001/ser01/index-still.html 3) http://jama.ama-assn.org/issues/v286n15/rfull/jsc10222.html 4) http://mosquito.who.int 5) http://www.malariavaccine.org/ 6) http://www.ehealthcube.co.uk/community/downloads/facing_the_challenge_one_year_on.pdf ?? ?? ?? ?? 1 | Page ...read more.

The above preview is unformatted text

This student written piece of work is one of many that can be found in our AS and A Level Healthcare section.

Found what you're looking for?

  • Start learning 29% faster today
  • 150,000+ documents available
  • Just £6.99 a month

Not the one? Search for your essay title...
  • Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

See related essaysSee related essays

Related AS and A Level Healthcare essays

  1. Marked by a teacher

    Investigating Diseases. I will be looking at and comparing communicable and non communicable diseases. ...

    4 star(s)

    This can cause them to become unfit, they may not be as active as they were before. Intellectually- They will find it hard to think about other things i.e. their future, education, friends, family and etc... Emotionally- they will feel upset and low self esteem about themselves.

  2. Complementary Therapies

    A counsellor is there to help you find your own way through your problems/issues without having a personal agenda. enabling people to see the range of possibilities before them, and supporting them while they go through the process of choosing the best one for them provides a safe confidential enviroment

  1. Unit 4-Human lifespan development

    beliefs, and parenting practices can all play a part in shaping morality. Some moral behaviors are passed on by way of verbal stories or structured lessons, such as religious parables or classroom teaching activities. However, more commonly, moral behavior is learned through direct observation and imitation.

  2. Research In Clinical Practise

    Both articles, therefore, fulfil the aims within Cormack's framework (2000). According to Parahoo (1997), there is no real right or wrong title, only a misleading or confusing one and neither title is misleading or confusing.

  1. Child development - patterns of development. To increase my awareness and knowledge of ...

    As I know from the case study, Marie was born premature and had to be put into an incubator for 10 days. Due to this fact it is possible to say that this may be the main reason why her weight is under the "Norm" for an average baby.

  2. Communicable and Non-Communicable Disease: Tuberculosis and Cystic Fibrosis

    or placental tissue (CVS) which is then tested to determine whether or not both of the foetus' CFTR genes are normal. As the disease is recessive, if the child possesses one normal and one faulty CFTR allele, he/she is a cystic fibrosis carrier.

  • Over 160,000 pieces
    of student written work
  • Annotated by
    experienced teachers
  • Ideas and feedback to
    improve your own work